logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Comparison of in vivo and in vitro measures of beryllium sensitization.

    Article - En anglais

    Chronic beryllium disease (CBD) diagnosis hinges on demonstrating a cell-mediated immune response to beryllium salts in vitro with the beryllium lymphocyte proliferation test (BeLPT).

    The BeLPT has found widespread application in screening for CBD and beryllium sensitization in populations of exposed workers.

    We hypothesized that the in vivo beryllium salt patch test may be of value as an adjunct to the BeLPT, rectifying false negative or ambiguous blood test results.

    We studied subjects with CBD (n=11), beryllium sensitization without disease (n=3), and control subjects with dermatitis (n=20).

    Evaluation included completion of a demographic questionnaire, blood BeLPT (if CBD or beryllium-sensitized), and beryllium patch testing with 0.1% and 1% beryllium sulfate (BeSO4) in petrolatum and in aqueous vehicles.

    Biopsies were performed at abnormal patch test sites in five subjects.

    The 1% aqueous BeSO4 proved superior either to 1% petrolatum or 0.1% solutions, producing positive reactions in all CBD and beryllium-sensitized subjects.

    We observed no long-term adverse reactions.

    Biopsies demonstrated spongiotic changes early, followed by noncaseating granulomas within 18 days.

    We conclude that the beryllium patch test can be used safely to clarify the sensitization state and diagnosis of CBD.

    Mots-clés Pascal : Béryllium, Toxicité, Homme, Bérylliose, Exposition professionnelle, Médecine travail, Mécanisme action, Diagnostic, Réponse immune, Sensibilisation, Test cutané, Patch, In vivo, In vitro, Appareil respiratoire pathologie, Poumon pathologie, Pneumoconiose, Maladie professionnelle, Biopsie, Peau, Test proliferation lymphocytaire

    Mots-clés Pascal anglais : Beryllium, Toxicity, Human, Berylliosis, Occupational exposure, Occupational medicine, Mechanism of action, Diagnosis, Immune response, Sensitization, Skin test, Patch, In vivo, In vitro, Respiratory disease, Lung disease, Pneumoconiosis, Occupational disease, Biopsy, Skin

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0405124

    Code Inist : 002B03L03. Création : 19/12/1997.